Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Signal Genetics Expands Oncology Pipeline with Acquisition of ChipDX

By LabMedica International staff writers
Posted on 14 Feb 2012
Signal Genetics (New York, NY, USA), a company focused on personalized medicine for cancer patients, will purchase all the assets of ChipDX (New York, NY, USA). More...
As part of the transaction, Signal Genetics will acquire BreastGeneDX, ColonGeneDX, and LungGeneDX, all diagnostic and prognostic tests in development by ChipDX.

Ryan VanLaar, PhD, CEO, and founder of ChipDX, will join Signal as head of bioinformatics. Financial details of the transaction were not disclosed.

The genetic tests represent novel products or improvements over other products currently on the market for lung, breast, and colon cancers. Signal will acquire ChipDX’s web-based interface, which will be used to enhance Signal’s physician web portal and allow for remote interpretation of test algorithms.

The acquired tests will leverage the technology platform currently in use by Signal Genetics and its subsidiaries and will provide economies of scale to the company’s currently commercialized multiple myeloma prognostic test, MyPRS Plus. The company will also use its recently established sales team as well as its commercial partners to launch the acquired products.

Ryan van Laar, CEO and founder of ChipDX, LLC, said, “Joining forces with Signal Genetics provides us with a vehicle to ultimately commercialize our strong portfolio of predictive molecular diagnostic tests. I look forward to leveraging the experience gained in the development of ChipDX to help Signal Genetics achieve its goals, and ultimately improve patient outcomes.”

Related Links:

Signal Genetics
ChipDX



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.